Omalizumab (Xolair) produced significantly greater treatment success than omalizumab-facilitated multiallergen oral immunotherapy (MOIT) in patients with 

new stage 2 results from the OUTMATCH trial

Omalizumab Outperforms Oral Immunotherapy for Multifood Allergy

Omalizumab received FDA approval in 2024 as the first agent indicated to reduce the risk of allergic reactions, including anaphylaxis, following accidental exposure to 1 or more foods. Oral immunotherapy using non-FDA-approved commercial products remains common in clinical practice, but no trial had directly compared the 2 approaches before OUTMATCH. This trial enrolled 117 participants with allergy to peanuts and ≥ 2 additional foods across 10 US academic centers.¹

"Both treatments can be effective, and both will provide protection from small exposures and even the ability to start eating the food directly," Robert A. Wood, MD, professor of pediatrics, Johns Hopkins University School of Medicine, told

. "The biggest difference we found was the side effects from oral immunotherapy were such a far larger group of patients really couldn't tolerate the therapy."

Participants (median age, 7 years) were randomized to active MOIT (n = 58) or active omalizumab (n = 59) following a 16-week open-label omalizumab run-in. MOIT was escalated toward a goal maintenance dose of 1000 mg per food (3000 mg total protein), while the omalizumab arm transitioned to 44 weeks of blinded injections. The primary endpoint was cumulative tolerated dose of ≥ 4044 mg for all 3 foods on double-blind, placebo-controlled food challenge.¹

In the intention-to-treat (ITT) population, omalizumab was superior to MOIT for the primary endpoint (36% vs 19%; odds ratio [OR], 2.6; 95% CI, 1.1-6.3; 

 =.03). This difference disappeared in the per-protocol population (OR, 1.2; 95% CI, 0.5-3.3; 

 =.66), reflecting a substantially higher discontinuation rate in the MOIT arm (49%) compared with omalizumab (12%) most driven by adverse events.¹

Omalizumab Safety versus Multiallergen Oral Immunotherapy

Omalizumab also showed superiority across secondary endpoints in the ITT population, including cumulative tolerated dose of ≥ 4044 mg for ≥ 2 foods (OR, 3.3; 95% CI, 1.5-7.3; 

 =.002) and for individual foods including peanuts (OR, 4.3; 95% CI, 1.9-9.7; 

 <.001), milk (OR, 6.2; 95% CI, 1.4-27.6; 

 =.02), and eggs (OR, 11.7; 95% CI, 1.9-70.2; 

 =.004). For protection against small unintentional exposures, 72% of the omalizumab arm tolerated ≥ 444 mg of all 3 allergens compared with 39% of the MOIT arm.¹

What did the OUTMATCH stage 2 trial show?

Omalizumab produced higher treatment success than omalizumab-facilitated multiallergen oral immunotherapy in the intention-to-treat population, but the difference largely disappeared once high MOIT discontinuation rates were accounted for in the per-protocol analysis.

How does omalizumab compare with oral immunotherapy for multifood allergy?


Both approaches showed similar efficacy among participants who completed treatment, but MOIT carried significantly higher rates of serious adverse events, epinephrine-treated reactions, and anaphylaxis, driving nearly half of MOIT participants to discontinue.

Is omalizumab safe for patients with multiple food allergies?


Across the full OUTMATCH program, no anaphylactic events were attributed to omalizumab injections, and reactions were largely limited to non-dose-limiting local injection-site reactions.

The MOIT arm carried a substantially heavier safety burden, with more serious adverse events (31% vs 0%), events treated with epinephrine (37% vs 7%) and events meeting anaphylaxis criteria (27% vs 2% [than the omalizumab arm. Investigators also identified 3 cases of biopsy-confirmed eosinophilic esophagitis in the MOIT group.¹

"The adverse event profile of omalizumab is very reassuring, and this phase of the study confirmed the adverse events are very small," Wood said. "We've now, in the entirety of OUTMATCH, not seen any anaphylactic events [with omalizumab].”

However, Wood noted that omalizumab has a black box warning for anaphylaxis with an estimated risk of 1 in 500 to 1 in 1000 patients.

“What that translates to is that the first doses are given under observation,” he said.

Wood noted reactions to omalizumab in the trial were largely limited to local injection-site reactions, consistent with prior stage 1 findings, and were not dose-limiting in any participant.

The investigators pointed to protocol-imposed rigidity in MOIT dosing, including the inability to adjust individual food doses, as a possible contributor to the arm's high discontinuation rate, suggesting real-world flexibility could improve tolerability. Additional trials comparing OIT with anti-IgE strategies, including cost-benefit analyses, are needed to guide personalized treatment selection.¹

Editor’s note: Reported disclosures for Wood include Genentech and Novartis Pharmaceuticals Corporation.

Wood RA, Togias A, Burk CM, et al. Treatment of multifood allergy with omalizumab or multiallergen oral immunotherapy: a randomized clinical trial. 

Derman C. Omalizumab Outperforms Multiallergen OIT for Multifood Allergy. HCPLive Published July 28, 2026. Accessed July 29, 2026. 

https://www.hcplive.com/view/omalizumab-outperforms-multiallergen-oit-multifood-allergy

Videos

Robert Wood, MD, discusses OUTMATCH data showing omalizumab beat multiallergen oral immunotherapy, though MOIT dropouts narrowed the gap.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Bryan Wells, MD, is a cardiovascular disease specialist at Emory Healthcare.

New data from Emory University and University Hospitals have indicated the potential for a comprehensive guideline to help clinicians quantify hemodynamically significant renal artery stenosis in patients with fibromuscular dysplasia (FMD).

FMD Peak Systolic Velocity May Lead to Comprehensive Clinical Guidelines

Presented at the 2026 International Fibromuscular Dysplasia (FMD) Think Tank and Symposium in Cleveland, Ohio, by Bryan Wells, MD, a cardiovascular disease specialist at Emory Healthcare, these data highlight a potential path forward for broader implementation of renal duplex ultrasound in this challenging disease, optimizing screening for non-atherosclerotic patients.

 that’s resistant to medications. You think about other sources of secondary hypertension, and so that’s part of the workup,” Wells told 

 in an exclusive interview. “For atherosclerosis, there have been studies that have validated this with angiography as well as hemodynamic parameters with invasive angiograms and pressure gradients and so forth, but that data doesn’t exist for fibromuscular dysplasia. We’re trying to avoid invasive procedures whenever possible, and to come up with safe and effective ways to do surveillance for these patients.”

FMD is an idiopathic, segmentary, non-inflammatory, non-atherosclerotic disease affecting all layers of small- and medium-caliber arteries. While the condition primarily affects the renal, carotid, and vertebral arteries, it can potentially affect any artery. FMD’s direct cause is unknown, although clinicians largely attribute it to a mix of genetics, physical factors, and hormones.

FMD most commonly appears in the kidneys of younger patients with resistant hypertension secondary to fibrodysplastic renal artery stenosis (RAS) and is found in roughly 1% of hypertensive patients. The disease represents the second leading cause of renovascular hypertension, after atherosclerotic disease. FMD-related lesions are most common in the renal arteries – several prior studies have indicated a substantially higher involvement of these vessels compared to carotid arteries.

Examination of the renal arteries by duplex ultrasound is a difficult process, requiring a skilled ultrasound technologist and several degrees of oversight. The ultrasound typically highlights evidence of arterial stenosis in the affected artery, including an increase in peak systolic velocity in the mid to distal portion of the main renal artery or a delayed systolic upstroke in arterial branches distal to the stenosis.

In the present datasets, investigators from Emory and University Hospitals combined their respective cohorts of patients with FMD who had had a renal duplex ultrasound followed by invasive angiogram within 6 months. Wells and colleagues compared duplex parameters such as peak systolic and diastolic velocity and renal to aortic ratio, aiming to find correlation with the invasive pressure wire gradient.

A total of 41 renal arteries from roughly 20 patients were included in the dataset. Wells and colleagues noted a moderate correlation between the highest peak systolic velocity, as scanned by renal duplex ultrasound, and a PD-PA ratio of <0.9. Additionally, the team determined the most effective and sensitive peak systolic velocity to be 300, which typically occurs in the mid to distal renal artery. Cleveland Clinic also conducted a similar study with similar results, with a cutoff peak systolic velocity of 275 cm/second – after consolidating all data, Wells and colleagues found a significant degree of consistency between the 2 studies. The team now plans to build out larger studies based on these pilot examinations, aiming to apply these results and evaluate their reproducibility and clinical value.

“We need to continue to collect our data at Emory and the other institutions and hopefully start to apply those and get more power in the data as we use this cutoff as an indication for an invasive renal angiogram,” Wells said. “It would be very nice to collaborate with more institutions and collect these data to see if it applies more broadly to this patient population.”

Editors’ Note: Wells reports no relevant disclosures.

Wells B, Sammak S. Renal Duplex for FMD: Data from Emory and University Hospitals. Presented at the 2026 International Fibromuscular Dysplasia (FMD) Think Tank and Symposium, Cleveland, OH. July 23-24, 2026

Varennes L, Tahon F, Kastler A, et al. Fibromuscular dysplasia: what the radiologist should know: a pictorial review. Insights Imaging. 2015;6(3):295-307. 

Olin JW, Gornik HL, Bacharach JM, et al. Fibromuscular dysplasia: State of the science and critical unanswered questions. Circulation. 2014;129(9):1048-1078. 

Bryan Wells, MD, breaks down new data from 3 universities that have produced a relatively consistent peak systolic velocity, indicating the potential for broad treatment guidelines.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Carolyn H. Baloh, MD, from the division of allergy and clinical immunology at Brigham and Women's Hospital, Harvard Medical School.

Non-Sesame Seed, Spice Allergies Can Trigger Severe Reactions

New data from the FARE (Food Allergy Research & Education) Patient Registry show non-sesame seed and herb/spice allergies can trigger 

and biphasic responses at rates comparable to sesame allergy.¹

"When patients report allergic reactions to non-sesame seeds, herbs, or spices, we should be cognizant these allergens can cause more severe reactions, including those requiring one or more doses of epinephrine or biphasic reactions," said Carolyn H. Baloh, MD, from the division of allergy and clinical immunology at Brigham and Women's Hospital, Harvard Medical School.

FARE Registry Reaction Severity Findings: Non-Sesame Seed, Herb/Spice

Investigators extracted deidentified survey data on 2601 participants reporting a sesame (n = 1195), non-sesame seed (n = 968), and/or herb or spice (n = 616) allergy from the FARE registry.¹ Data collection spanned August 24, 2017, to July 1, 2025, and the overall cohort was 51% male and 56% Caucasian, though demographics diverged sharply by allergen group.¹ Epinephrine was administered for approximately one-third of reported reactions.¹

In the mutually exclusive analysis, epinephrine use was reported by 42% of participants with sesame allergy, 40% with non-sesame seed allergy, and 29% with herb/spice allergy (

=.05).¹ Use of ≥ 1 epinephrine doses was numerically greater among the non-sesame seed-only group, though the difference did not reach statistical significance.¹ Biphasic reactions occurred across all 3 groups and were most frequent among participants with only herb/spice allergy (40%), compared with 17% in the sesame-only group and 34% in the non-sesame seed-only group.¹

Diagnosis Timing and Cross-Reactivity in Seed Allergy

Diagnosis occurred before 18 years of age in approximately 80% of participants across all 3 groups.¹ Diagnosis before 1 year of age was significantly more common with sesame allergy (18%) than non-sesame seed (7%) or herb/spice allergy (2%) (

 <.0001).¹ Most food allergy diagnoses were made by a healthcare provider, ranging from 89% for sesame to 78% for herbs/spices, with the remainder self-diagnosed.¹

Atopic comorbidities were frequently reported across allergen groups, including allergic rhinitis (46%), eczema (49%), and asthma (38%) among sesame-allergic participants.¹ Cross-reactivity among seed allergens remains a clinical challenge. Baloh said allergists should rely on a combination of clinical history, skin prick testing, specific IgE, and food challenges to guide management.¹

Baloh's group plans to use the registry to assess whether specific symptoms during food allergic reactions correlate with the causative allergen rather than patient age alone.¹ Baloh also noted that she wants to use the registry to learn more about the racial, socioeconomic, and geographic factors in food allergic reactions.

“It's worth keeping in mind that while the prevalence of these allergies is increasing, they're still relatively uncommon,” she said. “That said, these allergens can cause anaphylaxis, even anaphylaxis requiring multiple doses of epinephrine and biphasic reactions. It's always worth evaluating if a non-sesame seed or herb or spice is concerning for an allergic reaction. Allergists should really take a thorough history of all possible foods ingested at the time of a food reaction; they should consider the possibility of these hidden allergens.”

Watch part 1 of our interview with Baloh here: 

FARE Registry Reveals Disparities in Seed and Spice Allergies

Editor’s note: A reported disclosure for Baloh includes SANOFI-AVENTIS U.S. LLC.

Liu EY, Lopez S, Bufford JL, Laidlaw TM, Baloh CH. Seeds, Spices-Not Always so Nice: A Report on the FARE (Food Allergy Research & Education) Patient Registry. J Allergy Clin Immunol Pract. 2026. d

Baloh C. FARE Registry Reveals Disparities in Seed and Spice Allergies. HCPLive Published July 28, 2026. Accessed July 29, 2026. 

https://www.hcplive.com/view/fare-registry-disparities-seed-spice-allergies

New FARE registry data show epinephrine use and biphasic reactions occur across sesame, seed, and herb/spice allergies, according to Carolyn H. Baloh, MD.

Harrison Nguyen, MD, MBA, MPH, is a double board-certified dermatologist/Mohs micrographic surgeon and clinical researcher in Houston, Texas.

 has evolved in recent years, providing clinicians in the field with an expanding range of topical, biologic, and oral treatment options.

While these advances have created new opportunities to improve patient outcomes, they have also introduced greater complexity into the selection of drugs, requiring dermatologists to weigh disease severity, comorbidities, patient preferences, and quality-of-life considerations when determining the most appropriate medication.

 Conference in Nashville, Harrison Nguyen, MD, MBA, MPH, founder of Harrison Dermatology & Research Group, speaks on the key themes from his session, ‘Medical Crossfire.'

 He shared his views on tailoring treatment decisions to individual patients, identifying when to escalate from topical to systemic therapy, and the importance of shared decision-making:

You gave a talk at RAD titled ‘The Medical Crossfire.’ In light of this session, what are some of the most common areas of debate when choosing between topical therapies, oral agents, and biologics for atopic dermatitis?

 Well, I often say we're in a golden revolution of atopic dermatitis. We have, fortunately, several options for treating our patients, both from a topical standpoint and also systemic. As we're understanding more and more about these therapies, both ones that are established and emerging, we're trying to understand which patient will benefit from which therapy. For each therapy, we're understanding more and more about their biologic behavior, how they behave in certain manifestations of atopic dermatitis, and, of course, which patient would benefit the most based on those characteristics.

So, I presented a case of a teenage patient with atopic dermatitis with a significant history of atopic disease in that patient's family. The mom has a history of asthma. Dad has a history of food allergies and allergic rhinitis. Actually, a younger sibling has developed new-onset chronic spontaneous urticaria. All type 2 inflammatory diseases. In my presentation, I argued that the best treatment for this patient, once we made the decision to escalate from a topical treatment to a systemic treatment, is dupilumab. Why is that? Dupilumab blocks not just IL-13 but IL-4 as well. IL-4 is critical in so many mechanisms of type 2 inflammation.

It's critical in class switching for antibodies is critical. Critical in Th2-mediated disease. So if we can interfere and block IL4 in addition to IL13, our patients will really benefit from it. Not only are we able to control their symptoms of atopic dermatitis, but we're also seeing emerging data that we're able to prevent the development of other type two inflammatory diseases, things like asthma, things like allergic rhinitis. Then also [we may be] able to address other comorbidities that may emerge, such as chronic spontaneous urticaria.

When you're evaluating a patient with moderate to severe disease, what factors most strongly impact your decision to then escalate from topicals to a systemic?

 It's quality of life. The impact on quality of life is the single most important driver of escalation of therapy. It's the impact on the itch. So, is a patient so itchy that it's interfering with his or her ability to sleep, his or her ability to function, his or her ability to work or to study? Is the topical burden so overwhelming that it’s also interfering with quality of life? Sometimes for parents who are caregivers for patients or adolescents with atopic dermatitis, the burden of having to apply topicals can be really challenging for caregivers.

We really want to understand the patient's journey, the patient's impact on quality of life, and then from there, we also go into things like preferences, comorbidities, and of course, manifestations of disease. We stratify based on specialty site involvement, such as head and neck atopic dermatitis, atopic dermatitis affecting the hands and the feet, because these types of involvement in specific areas will also determine our selection as well.

There's a growing number of available therapies. How has your approach to treatment sequencing evolved? Are there situations where you're moving quickly towards oral or biological therapies that maybe more quickly than you would have several years ago?

 I believe that we should always meet the patient where they are. So it doesn't matter if they walk into my clinic for the first time and they've never tried a topical treatment, but they're covered from head to toe with atopic dermatitis…I'm not going to delay treatment and say, ‘Okay, we're going to try topicals first.’ We know that a patient is a systemic or biologic patient, right? So I try to meet the patient where they are in their atopic dermatitis journey. You know, for some patients, we do start with topicals, but when the burden of disease is impactful, no matter what time they're meeting me, I try to meet them where they are.

Typically, in my practice, I will usually start with a biologic. We have four biologics available: dupilumab, lebrikizumab, tralokinimab, and nemolizumab. But we also have 2 systemic JAK inhibitors: abrocitinib and upadacitinib. And for my patients who I think will benefit from the get-go from JAK inhibition right away, I have no hesitation to put them on a JAK inhibitor and not step through a biologic. But that being said, the majority of the time I do start with a biologic. It's not necessarily escalating faster. It's just meeting the patient where they are.

For clinicians who are attending this session, what practical takeaways do you hope they take away regarding how to individualize treatment selection and engage patients in shared decision-making?

 I hope the audience took away key principles about understanding each atopic dermatitis patient's presentation preferences and journey. Not every atopic dermatitis patient is the same, and we want to choose the best treatment for the patient in front of us. Take into account the patient's presentation. What anatomical sites are affected, the patient's comorbidities, and patient preferences, so that we can really cater our treatment to our patient. Sometimes, I think it feels like we have good treatment for atopic dermatitis, and we can just do 1 treatment for every patient in front of us. We would probably get good results, ranging from good to excellent for all our patients, or at least for the vast majority of them. But I think if we take a customized, catered approach, we can get excellent results for each and every 1 of our patients based on their characteristics, disease course, and their patient preferences.

Editor’s note: Nguyen had no relevant financial disclosures of note.

Nguyen H, Bunick C, Cotter D, Shahriari M. Medical Crossfire and Clinical Case Challenge. Session presented at: 2026 Revolutionizing Atopic Dermatitis Conference; June 17-19, 2026; Nashville, TN.

Nguyen H. Emerging Evidence in Atopic Dermatitis Management, With Harrison Nguyen, MD, MBA, MPH. HCPLive. June 19, 2026. Accessed July 29, 2026. 

https://www.hcplive.com/view/emerging-evidence-atopic-dermatitis-management-harrison-nguyen-md-mba-mph

Articles

Therapeutic options for atopic dermatitis now span multiple topicals, biologics, and oral systemic agents, increasing both opportunity and decision complexity. Treatment escalation is primarily driven by quality-of-life impairment, especially pruritus, sleep disruption, functional limitation, and topical-treatment burden for patients and caregivers. Systemic selection should incorporate disease phenotype and anatomic distribution, comorbid type 2 inflammatory conditions, and patient preferences. Dupilumab may be favored when broader type 2 blockade is desired. Sequencing should “meet patients where they are,” including direct initiation of biologics or JAK inhibitors when appropriate.

How should clinicians choose atopic dermatitis treatments? Harrison Nguyen, MD, discusses personalized therapy and when to escalate care.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Q&A: Which Factors Guide the Choice Between JAKi, Biologics, or Other AD Drugs?

Andrew Adams MD, PhD, is Professor of Surgery and Chief of the Division of Transplantation at the University of Minnesota

New long-term data from the phase 2 BESTOW extension study showed kidney transplant recipients treated with the investigational anti-CD154 monoclonal antibody tegoprubart maintained higher estimated glomerular filtration rate (eGFR) than those receiving tacrolimus through 18 months, with no biopsy-proven acute rejection events observed after 6 months among tegoprubart-treated patients.

In this Q&A, Andrew Adams, MD, PhD, discusses the clinical significance of the findings, the potential role of CD154 blockade in kidney transplantation, and what the upcoming phase 3 program will need to demonstrate.

Q&A: Long-Term Tegoprubart Data in Kidney Transplantation, With Andrew Adams

HCPLive: How meaningful was the absence of biopsy-proven acute rejection after six months with tegoprubart?

 That's a great question. What we saw—and this is similar to other agents in the co-stimulation blockade class—is that most, if not all, rejection tends to occur early after transplant. While we did see some rejection early on with tegoprubart, when we followed patients out to 18 months, the overall rate of rejection became almost equivalent between tacrolimus and tegoprubart. The difference was really the timing of those events.

What was especially interesting was what happened after those rejection episodes. Patients who experienced rejection on tegoprubart, were treated, and remained on therapy didn't appear to pay the same penalty in terms of kidney function. When we compared patients who experienced rejection on tegoprubart with those who rejected on tacrolimus, the tegoprubart-treated patients maintained substantially better kidney function.

That likely relates to a couple of things, including antibody development and the effects of calcineurin inhibitors on scar formation within the kidney during rejection. Even if rejection occurred, patients receiving a more targeted therapy like tegoprubart appeared to preserve kidney function better over the long term, which is ultimately what we're trying to achieve.

HCPLive: What do these findings suggest about CD154 blockade as an alternative approach to calcineurin inhibitor-based immunosuppression?

 Over nearly 30 years of research, we've learned that the CD40-CD154 pathway is one of the most important pathways involved in transplant rejection. There are several T-cell co-stimulation pathways that matter, but if you had to choose one, this is probably the most important.

The challenge historically wasn't understanding the pathway—it was finding a way to block it safely. Earlier antibodies targeting this pathway had complications of their own. Tegoprubart was engineered to overcome those issues, and what we've now seen across studies is that it appears to be well tolerated while also effectively preventing rejection and maintaining good kidney function after transplant.

Beyond kidney transplantation, this pathway may become increasingly important for other areas of transplantation. In xenotransplantation, where genetically modified pig organs are transplanted into human recipients, CD40-CD154 blockade appears to be one of the critical pathways for achieving long-term graft survival in preclinical models. We've already begun to see that approach used on a case-by-case basis in clinical settings, so I think this pathway has implications well beyond traditional kidney transplantation.

HCPLive: As tegoprubart moves into phase 3 development, what will be most important to demonstrate?

 Over the last 50 or 60 years, transplantation has evolved tremendously. By the 1980s and 1990s we had highly effective immunosuppressive therapies like cyclosporine and tacrolimus, and they've given us outstanding first-year transplant success rates—98% to 99% in kidney transplantation.

The challenge is that those medications also carry significant long-term burdens. Patients experience medication-related side effects, and over time we still see loss of kidney function that can ultimately lead to a return to dialysis or the need for another transplant.

The opportunity with a therapy like tegoprubart is to determine whether we can maintain effective immune control while preserving kidney function over the long term using a different approach. As we move into phase 3, it will be important to confirm what we've seen in the phase 1b and phase 2 studies—that the therapy is safe, well tolerated, and capable of reducing some of the side effects associated with traditional calcineurin inhibitor therapy.

One of the more exciting findings from the extension study was the patient-reported outcomes. It's not just about objective measures like kidney function, hypertension, or new-onset diabetes. It's also about how patients feel. Many patients on tacrolimus describe neurologic side effects, including brain fog, where they simply don't feel like themselves. As patients transition away from those traditional medicines, we're seeing improvements in those symptoms with a therapy that's more specifically targeting the immune response.

HCPLive: Is there anything else you'd like clinicians to know about this program?

 I think it's an exciting time across solid organ transplantation, not just kidney transplantation. If the phase 3 data support what we've seen so far, therapies like tegoprubart could have implications for liver, heart, and lung transplantation, where the burden of immunosuppression can be even greater because rejection is more common.

In liver transplantation, for example, we also see downstream effects on kidney function, diabetes risk, and neurologic side effects from current immunosuppressive therapies. Success in kidney transplantation could help establish the foundation for evaluating this approach in other transplant populations.

Beyond traditional organ transplantation, there are also exciting areas like islet cell transplantation and xenotransplantation. Early work from groups such as the University of Chicago and others is exploring tegoprubart in those settings as well. If future studies continue to support these findings, this type of targeted immunomodulation could expand our options for treating patients with end-stage organ disease.

Editor’s Note: Adams reported serving as an advisory board member for Eledon Pharmaceuticals, Miromatrix, and Sanofi, and receiving research funding from Regeneron and Sanofi.

Eledon Pharmaceuticals, Inc. Eledon presents long-term extension phase 2 BESTOW results at American Transplant Congress showing sustained higher kidney function and improved patient-reported outcomes with tegoprubart compared with tacrolimus. News release. GlobeNewswire. June 22, 2026. Accessed July 10, 2026. 

https://www.globenewswire.com/news-release/2026/06/22/3315172/0/en/eledon-presents-long-term-extension-phase-2-bestow-results-at-american-transplant-congress-showing-sustained-higher-kidney-function-and-improved-patient-reported-outcomes-with-tego.html

Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. 

Long-term follow-up from the phase 2 BESTOW extension suggests tegoprubart (anti-CD154) can sustain higher eGFR versus tacrolimus through 18 months, with biopsy-proven acute rejection events concentrated early and none occurring after 6 months on tegoprubart. Rejection timing appeared more than incidence to differentiate regimens, and patients who rejected on tegoprubart maintained better renal function after treatment than those rejecting on tacrolimus, consistent with reduced calcineurin inhibitor–associated nephrotoxicity. Patient-reported neurologic symptom improvements further support phase 3 evaluation.

Andrew Adams discusses tegoprubart in kidney transplantation and the phase 2 BESTOW data on kidney function, rejection, and immunosuppression.


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Long-Term Tegoprubart Data in Kidney Transplantation, With Andrew Adams

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

PAH specialists discuss prostacyclin use, pericardial effusion risks, erythrocytosis, and what real-world super-responders look like in practice.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

PAH in 2026: Algorithm Shifts and Real-World Gaps

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Topline data from the largest disease-modification trial in biliary atresia show no benefit over placebo for the primary endpoint, though the established safety profile in approved indications was maintained.


Hepatology

Odevixibat Fails to Improve Native Liver Survival in Phase 3 BOLD Trial for Biliary Atresia

Podcasts

In this episode of The Medical Sisterhood, physician entrepreneurship is explored as Meagen McCusker, MD, shares lessons on private practice, leadership, and career.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

The Medical Sisterhood, with Mona Shahriari, MD

The Medical Sisterhood, hosted by Mona Shahriari, MD, is a podcast dedicated to empowering female physicians by providing a platform for shared experiences, mentorship, and support. 

Each episode delves into the unique challenges women in medicine face, including work-life balance, leadership roles, and overcoming gender biases. Shahriari aims to inspire women to lead fulfilling professional and personal lives on their own terms through candid discussions and expert interviews. 

e as we foster a community where women can uplift and support each other in achieving their goals!

The Medical Sisterhood: From Employee to Entrepreneur, With Meagen McCusker, MD

Hunter Champion, MD, PhD, is the director of the Heart Failure and Pulmonary Hypertension program at Southeastern Cardiology Associates and a clinical associate professor of medicine at Mercer University.

Hunter Champion, MD, PhD, covers his experience with furosemide injections in reducing hospital readmissions and how the ReadyFlow may decrease them further.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Chronic Kidney Disease

Furoscix ReadyFlow (Furosemide) and its Impact on HF, CKD Edema Treatment

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

In the OUTMATCH stage 2 randomized trial, omalizumab achieved greater intention-to-treat success than multiallergen oral immunotherapy.

Omalizumab Outperforms Multiallergen OIT for Multifood Allergy

A FARE Patient Registry analysis finds herb and spice allergies disproportionately affect Black, Hispanic, and lower-income patients, Carolyn Baloh, MD, says.

Cary James is the Chief Executive at The World Hepatitis Alliance

World Hepatitis Day survey findings reveal gaps in chronic hepatitis B awareness and liver cancer risk perception, with Cary James discussing elimination efforts.

Survey Reveals Low Awareness of Chronic Hepatitis B’s Link to Liver Cancer

Walter J. Liszewski, MD, is an associate professor of dermatology and cancer epidemiology at Northwestern University Feinberg School of Medicine.

How is drug selection evolving in atopic dermatitis? Walter Liszewski, MD, discusses personalized therapy and long-term care.

What Factors Should Guide Atopic Dermatitis Treatment Selection? With Walter Liszewski, MD

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

The FDA has officially granted Fast Track designation to HTX-001 for the treatment of non-obstructive hypertrophic cardiomyopathy.

Cardiomyopathy

FDA News

FDA Grants Fast Track Designation to HTX-001 for nHCM

IgA nephropathy is common to specialists but rare to the physicians who see patients first. The panel examines why the disease is caught late and what screening and education could change.

Latest News

Omalizumab Outperforms Oral Immunotherapy for Multifood Allergy

FMD Peak Systolic Velocity May Lead to Comprehensive Clinical Guidelines

Non-Sesame Seed, Spice Allergies Can Trigger Severe Reactions

Q&A: Which Factors Guide the Choice Between JAKi, Biologics, or Other AD Drugs?

Long-Term Tegoprubart Data in Kidney Transplantation, With Andrew Adams